PharmaTher’s Potential Breakthrough in Monkeypox Treatment
Company Announcements

PharmaTher’s Potential Breakthrough in Monkeypox Treatment

Story Highlights

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd.’s subsidiary, Sairiyo Therapeutics, has discovered that cepharanthine may have the potential to combat monkeypox by binding to the virus’s proteins. This finding, from an independent drug screening study, suggests that cepharanthine could play a role in understanding and treating the virus. While promising, the company has clarified that there are no claims yet that cepharanthine can treat or cure monkeypox.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPharmaTher Closes in on FDA Ketamine Approval Date
TheFlyPharmaTher receives GDUFA goal date of October 29 for ketamine NDA
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App